Published in J Thromb Haemost on October 22, 2007
A kernel-based integration of genome-wide data for clinical decision support. Genome Med (2009) 1.26
The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer (2010) 1.14
The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. Br J Cancer (2014) 1.12
Analysis of the Fibrinogen and Neutrophil-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis. Medicine (Baltimore) (2015) 1.00
Prognostic significance of preoperative fibrinogen in patients with colon cancer. World J Gastroenterol (2014) 0.92
The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients. World J Urol (2014) 0.89
Characterization of the chemotactic and mitogenic response of SMCs to PDGF-BB and FGF-2 in fibrin hydrogels. J Biomed Mater Res A (2010) 0.86
Clinical and Prognostic Significance of Preoperative Plasma Fibrinogen Levels in Patients with Operable Breast Cancer. PLoS One (2016) 0.80
Prognostic Impact of Pretreatment Plasma Fibrinogen in Patients with Locally Advanced Oral and Oropharyngeal Cancer. PLoS One (2016) 0.79
Preoperative peripheral plasma fibrinogen level is an independent prognostic marker in penile cancer. Oncotarget (2016) 0.79
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers. J Cancer Res Clin Oncol (2012) 0.77
Influence of Stromal Components on Lung Cancer Carcinogenesis. J Carcinog Mutagen (2013) 0.77
Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma. Ups J Med Sci (2010) 0.77
Preoperative Plasma Fibrinogen Level Represents an Independent Prognostic Factor in a Chinese Cohort of Patients with Upper Tract Urothelial Carcinoma. PLoS One (2016) 0.76
Networking with fibrinogen: a prerequisite for fibroblast growth factor-2 (FGF-2)-stimulated tumor growth? J Thromb Haemost (2008) 0.75
The comparison of plasma D-dimer levels in benign and malignant tumors of cervix, ovary and uterus. Int J Hematol Oncol Stem Cell Res (2015) 0.75
Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply. Int J Mol Sci (2017) 0.75
Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma: A Meta-Analysis. Biomed Res Int (2017) 0.75
Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer. Oncol Lett (2015) 0.75
Elevated fibrinogen plasma level is not an independent predictor of poor prognosis in a large cohort of Western patients undergoing surgery for colorectal cancer. World J Gastroenterol (2016) 0.75
Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy. Prostate Cancer Prostatic Dis (2016) 0.75
Clinical significance of coagulation factors in operable colorectal cancer. Oncol Lett (2017) 0.75
Fibrinogen and D-dimer levels in prostate cancer: Preliminary results. Prostate Int (2017) 0.75
Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma. Oncotarget (2017) 0.75
Plasma fibrinogen and serum albumin levels (FA score) act as a promising prognostic indicator in non-small cell lung cancer. Onco Targets Ther (2017) 0.75
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost (2007) 3.22
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res (2010) 1.93
NF-kappa B-dependent inhibition of apoptosis is essential for host cellsurvival during Rickettsia rickettsii infection. Proc Natl Acad Sci U S A (1998) 1.92
Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood (2000) 1.74
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz. Ultrasound Med Biol (2000) 1.55
Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost (1997) 1.40
Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. AJR Am J Roentgenol (1990) 1.39
Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene (2000) 1.38
Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood (1993) 1.36
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg (1994) 1.26
Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem (1998) 1.25
Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest (1987) 1.22
Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol (2001) 1.19
Enhancement of fibrinolysis with 40-kHz ultrasound. Circulation (1998) 1.19
Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood (1980) 1.18
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Ann Intern Med (1986) 1.17
Polonium-210 analyses of vegetables, cured and uncured tobacco, and associated soils. Science (1965) 1.11
Structural studies of the functional heterogeneity of von Willebrand protein polymers. Blood (1981) 1.10
Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation. Infect Immun (1997) 1.09
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. Circulation (1985) 1.08
Invasion of human coronary artery endothelial cells by Streptococcus mutans OMZ175. Oral Microbiol Immunol (2009) 1.07
Modulation of leukocyte behavior by an inflamed extracellular matrix. Dev Immunol (2000) 1.07
Conserved sequence homology of cysteine-rich regions in genes encoding glycoprotein A in Pneumocystis carinii derived from different host species. Infect Immun (1994) 1.05
Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA (1983) 1.05
Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost (1994) 1.04
Effect of 40-kHz ultrasound on acute thrombotic ischemia in a rabbit femoral artery thrombosis model: enhancement of thrombolysis and improvement in capillary muscle perfusion. Circulation (2000) 1.04
Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. Blood (1998) 1.04
Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med (1983) 1.02
Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood (1980) 1.02
Ultrasound enhancement of thrombolysis and reperfusion in vitro. J Am Coll Cardiol (1993) 1.01
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med (1992) 0.99
Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation (2000) 0.99
Hemolysis in vivo from exposure to pulsed ultrasound. Ultrasound Med Biol (1997) 0.98
Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood (1986) 0.98
Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost (1996) 0.97
Structural studies of fibrinolysis by electron microscopy. Blood (1998) 0.97
Low-intensity ultrasound increases endothelial cell nitric oxide synthase activity and nitric oxide synthesis. J Thromb Haemost (2004) 0.97
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost (2001) 0.95
Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis (2001) 0.95
Challenges of rare disease research: limited patients and competing priorities. Haemophilia (2011) 0.94
Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost (2006) 0.93
Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med (1998) 0.93
Ultrasound increases flow through fibrin gels. Thromb Haemost (1995) 0.93
Mechanisms of cytopenia in human immunodeficiency virus infection. Blood Rev (1994) 0.93
Principles of access to health care. Access to Health Care Task Force, American Heart Association. Circulation (1993) 0.92
Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res (2000) 0.92
Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost (2004) 0.92
Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB. Infect Immun (1998) 0.92
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost (2003) 0.92
Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy. Neurology (2002) 0.92
Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood (1995) 0.92
Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol (1996) 0.91
Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem (1980) 0.91
Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. Blood (1993) 0.91
Lower risk of thromboembolic disease after total hip replacement with non-cemented than with cemented prostheses. Lancet (1986) 0.90
Concepts of clot lysis. Annu Rev Med (1986) 0.89
Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. Thromb Res (1994) 0.89
Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem (1999) 0.89
Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. J Biol Chem (1993) 0.88
Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest (1980) 0.88
TNF-alpha associated with extracellular matrix fibronectin provides a stop signal for chemotactically migrating T cells. J Immunol (2000) 0.88
Plasmin degradation of cross-linked fibrin. Ann N Y Acad Sci (1983) 0.88
Cloning and characterization of a conserved region of human and rhesus macaque Pneumocystis carinii gpA. Gene (1995) 0.88
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med (2001) 0.88
Polarized secretion of fibrinogen by lung epithelial cells. Am J Respir Cell Mol Biol (1997) 0.87
Ultrasound enhancement of rabbit femoral artery thrombolysis. Cardiovasc Surg (1997) 0.87
FGF-2 but not FGF-1 binds fibrin and supports prolonged endothelial cell growth. J Thromb Haemost (2003) 0.87
Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. Biochemistry (1984) 0.87
Molecular characterization of mouse Pneumocystis carinii surface glycoprotein A. DNA Res (1998) 0.87
Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood (1996) 0.87
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. Biochim Biophys Acta (1983) 0.86
Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. J Clin Invest (1992) 0.86
15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. J Thromb Haemost (2008) 0.86
Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous. Am J Med (1984) 0.86
Magnetic resonance imaging of blood and clots in vitro. Invest Radiol (1990) 0.86
Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med (1990) 0.85
Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost (1999) 0.85
Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost (2010) 0.85
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
Geologic migration potentials of technetium-99 and neptunium-237. Science (1979) 0.85
Increased expression of plasminogen activator inhibitor-1 in R. rickettsii-infected endothelial cells. Thromb Haemost (1996) 0.85
Integrin alphavbeta3-mediated endocytosis of immobilized fibrinogen by A549 lung alveolar epithelial cells. Am J Respir Cell Mol Biol (2001) 0.85
Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices. Blood (1997) 0.84
Demonstration of in situ fibrin degradation in pathologic thrombi. Blood (1984) 0.83
Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. Blood (1989) 0.83
The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. Blood (1989) 0.83
Effect of acoustic cavitation on platelets in the presence of an echo-contrast agent. Ultrasound Med Biol (1998) 0.82
Embolic complications of calf thrombosis following total hip arthroplasty. J Arthroplasty (1993) 0.82
Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest (1989) 0.82
A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost (1982) 0.81
Ultrasound accelerates urokinase-induced thrombolysis and reperfusion. Am Heart J (1994) 0.81
Physiologic regulation and pathologic disorders of fibrinolysis. Hum Pathol (1987) 0.81
Cnm is a major virulence factor of invasive Streptococcus mutans and part of a conserved three-gene locus. Mol Oral Microbiol (2013) 0.81
Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost (2003) 0.81
Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost (2000) 0.81